Sigrid Therapeutics obtains US patent covering the use of a novel silica-based biomaterial SiPore15® for the treatment and prevention of obesity
Stockholm, Sweden July 1, 2020. Sigrid Therapeutics, a Swedish clinical-stage technology company specializing in the prevention of type-2 diabetes and obesity, today announced that the Company has been granted a US patent by the United States Patent and Trademark Office (USPTO). The patent covers the use of the Company’s breakthrough, mesoporous silica particles (MSP)-based device SiPore15® for lowering of body fat, prevention and treatment of obesity. The patent (US 10,695,294) provides exclusive rights to the exploitation of the Company’s lead product in the US until 2033.
The US patent follows previously granted patents in key commercial territories including Japan, Australia, Canada and Israel among others, covering the platform technology SiPore® and the Company’s lead product SiPore15® for use as a pharmaceutical and dietary ingredient in the prevention and treatment of metabolic diseases. Sigrid also continues to pursue patent protection in other key markets and expects further granted patents to follow.
Sana Alajmovic, Co-founder & CEO, Sigrid Therapeutics, comments:
“This granted patent further strengthens Sigrid’s global IP portfolio while significantly enlarging the commercial attractiveness of SiPore15® to include the prevention and treatment of obesity in the most important global market. The recognition of our product’s inventiveness and novelty validates our expertise in terms of developing innovative and patentable silica-based biomaterials for the prevention and treatment of diabetes and its related diseases."
For more information, please contact:
Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics
Phone: +46 72 389 3396,
Email: sana@sigridthx.com
About SiPore®
Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes. Studies in mice published in Nanomedicine1 have shown that food efficiency was reduced by 33% leading to a positive effect on metabolic profile with significant lower levels of adipose tissue formation and leptin production, together with lower levels of circulating insulin. Weight gain was thus sufficiently attenuated. Additional pre-clinical and clinical results published in Advanced Healthcare Materials2 confirm these findings and are compatible with a mode of action whereby a portion of the enzymes are trapped inside the MSP resulting in an enzyme-blocking effect reducing the break-down of food and thus reducing the energy uptake into the body.
About Sigrid Therapeutics
Sigrid Therapeutics (Sigrid) is a clinical-stage technology startup pioneering a new class of engineered biomaterials to prevent and treat metabolic disease and disorders, including type 2 diabetes and obesity. The Company’s lead product candidate, SiPore15®, is an orally-administered medical device based on the Company’s proprietary platform technology, SiPore®. Designed to act locally in the gut, SiPore15®, consists of precisely engineered micron-sized silica particles with tailored porosity. Clinical data confirms the product’s beneficial effects on a range of metabolic parameters and its excellent safety profile1-3. Upon its approval, SiPore15®, will be the first medical device available for reduction of blood sugar levels in people at risk of developing type 2 diabetes. https://www.sigridthx.com/
- Mesoporous Silica with Precisely Controlled Pores Reduces Food Efficiency and Suppresses Weight Gain in Mice, Nanomedicine, 2020, https://www.futuremedicine.com/doi/10.2217/nnm-2019-0262
- Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans, Advanced Healthcare Materials, 2020, https://doi.org/10.1002/adhm.202000057
- Large pore mesoporous silica induced weight loss in obese mice, Nanomedicine, 2014, https://www.futuremedicine.com/doi/abs/10.2217/nnm.13.138
